Alice Tsang Shaw, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Alice Shaw and Jessica Lin.
Connection Strength
10.946
-
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21.
Score: 0.887
-
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2020 02; 15(2):258-265.
Score: 0.841
-
Refining precision cancer therapy in ALK-positive NSCLC. EBioMedicine. 2019 Mar; 41:9-10.
Score: 0.800
-
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. J Thorac Oncol. 2019 04; 14(4):683-690.
Score: 0.791
-
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140.
Score: 0.778
-
Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol. 2017 11; 12(11):1611-1625.
Score: 0.722
-
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017 02; 7(2):137-155.
Score: 0.695
-
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
Score: 0.693
-
Raising the bar on first-line immunotherapy in lung cancer. Lancet Oncol. 2017 01; 18(1):2-3.
Score: 0.688
-
Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? J Clin Oncol. 2016 10 01; 34(28):3363-5.
Score: 0.671
-
Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer. 2016 07; 2(7):350-364.
Score: 0.668
-
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2022 02; 7(1):100342.
Score: 0.244
-
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909.
Score: 0.231
-
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Clin Lung Cancer. 2020 03; 21(2):153-159.e3.
Score: 0.210
-
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clin Cancer Res. 2019 11 15; 25(22):6662-6670.
Score: 0.207
-
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol. 2019 05; 14(5):816-824.
Score: 0.199
-
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018 10; 8(10):1227-1236.
Score: 0.193
-
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018 10; 13(10):1530-1538.
Score: 0.191
-
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
Score: 0.189
-
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 04 20; 36(12):1199-1206.
Score: 0.186
-
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 2017.
Score: 0.181
-
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 11; 11(11):2027-2032.
Score: 0.169
-
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859.
Score: 0.057
-
Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements. Cancers (Basel). 2020 Mar 15; 12(3).
Score: 0.054
-
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2535-2545.
Score: 0.054
-
Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2020 04; 214(4):766-774.
Score: 0.053
-
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Exp Hematol Oncol. 2019; 8:24.
Score: 0.052
-
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. J Thorac Oncol. 2018 11; 13(11):e226-e227.
Score: 0.049
-
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
Score: 0.049
-
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.048
-
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 04; 13(4):550-558.
Score: 0.047
-
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.